tiprankstipranks
Arrowhead Pharmaceuticals (GB:0HI3)
LSE:0HI3

Arrowhead Pharmaceuticals (0HI3) Share Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

0HI3 Analyst Ratings

Moderate Buy
8Ratings
5 Buy
3 Hold
0 Sell
Based on 8 analysts giving stock ratings to
Arrowhead
Pharmaceuticals
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

0HI3 Stock 12 Month Forecast

Average Price Target

$49.00
▲(97.58% Upside)
Based on 8 Wall Street analysts offering 12 month price targets for Arrowhead Pharmaceuticals in the last 3 months. The average price target is $49.00 with a high forecast of $90.00 and a low forecast of $27.00. The average price target represents a 97.58% change from the last price of $24.80.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"plus_tr_sans","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"21":"$21","56":"$56","91":"$91","38.5":"$38.5","73.5":"$73.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":90,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n  <span style=\"color:#199ca5\">$90.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":49,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n  <span style=\"color:#828080\">$49.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":27,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n  <span style=\"color:#912767\">$27.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[21,38.5,56,73.5,91],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2023","6":"Nov<br/>2023","9":"Feb<br/>2024","12":"May<br/>2024","25":"May<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,24.295,29.349230769230772,34.40346153846154,39.45769230769231,44.51192307692308,49.56615384615385,54.620384615384616,59.674615384615386,64.72884615384615,69.78307692307692,74.83730769230769,79.89153846153846,84.94576923076923,{"y":90,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,24.295,26.19538461538462,28.095769230769232,29.99615384615385,31.896538461538462,33.79692307692308,35.697307692307696,37.59769230769231,39.49807692307692,41.39846153846154,43.298846153846156,45.199230769230766,47.09961538461539,{"y":49,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,24.295,24.503076923076925,24.71115384615385,24.919230769230772,25.127307692307692,25.335384615384616,25.54346153846154,25.751538461538463,25.959615384615386,26.16769230769231,26.37576923076923,26.583846153846153,26.791923076923077,{"y":27,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":36.256,"date":1684454400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.581,"date":1685664000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.148,"date":1688688000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.058,"date":1691107200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.06,"date":1693526400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.69,"date":1696550400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.1,"date":1698969600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.078,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.392,"date":1704412800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.21,"date":1706832000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.55,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.172,"date":1712275200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.295,"date":1714694400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$90.00Average Price Target$49.00Lowest Price Target$27.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
UBS
$75.00
Buy
202.42%
Upside
Reiterated
02/07/24
Arrowhead price target lowered to $75 from $78 at UBSArrowhead price target lowered to $75 from $78 at UBS
Bernstein
$32.00
Hold
29.03%
Upside
Reiterated
01/02/24
Arrowhead price target raised to $32 from $27 at BernsteinArrowhead price target raised to $32 from $27 at Bernstein
Cantor Fitzgerald
$47.00
Buy
89.52%
Upside
Reiterated
08/07/23
Goldman Sachs
$68.00
Buy
174.19%
Upside
Reiterated
06/08/23
Goldman Sachs Reaffirms Their Buy Rating on Arrowhead Pharmaceuticals (ARWR)

Best Analysts Covering Arrowhead Pharmaceuticals

Which Analyst Should I Follow If I Want to Buy GB:0HI3 and Sell After:
1 Month
Edward TenthoffPiper Sandler
Success Rate
12/22 ratings generated profit
55%
Average Return
+0.43%
reiterated a buy rating 13 days ago
Copying Edward Tenthoff's trades and holding each position for 1 Month would result in 54.55% of your transactions generating a profit, with an average return of +0.43% per trade.
dummydummy
Success Rate
0/0 ratings generated profit
0%
Average Return
0.00%
a rating ―
Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.
Premium Content
Find out which analyst has the highest Average Return & Success Rate
Go Premium
3 Months
Keay NakaeChardan Capital
Success Rate
20/35 ratings generated profit
57%
Average Return
+10.77%
reiterated a buy rating 3 months ago
Copying Keay Nakae's trades and holding each position for 3 Months would result in 57.14% of your transactions generating a profit, with an average return of +10.77% per trade.
dummydummy
Success Rate
0/0 ratings generated profit
0%
Average Return
0.00%
a rating ―
Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.
Premium Content
Find out which analyst has the highest Average Return & Success Rate
Go Premium
1 Year
Keay NakaeChardan Capital
Success Rate
19/35 ratings generated profit
54%
Average Return
+37.67%
reiterated a buy rating 3 months ago
Copying Keay Nakae's trades and holding each position for 1 Year would result in 54.29% of your transactions generating a profit, with an average return of +37.67% per trade.
2 Years
Keay NakaeChardan Capital
Success Rate
13/35 ratings generated profit
37%
Average Return
+62.45%
reiterated a buy rating 3 months ago
Copying Keay Nakae's trades and holding each position for 2 Years would result in 37.14% of your transactions generating a profit, with an average return of +62.45% per trade.
dummydummy
Success Rate
0/0 ratings generated profit
0%
Average Return
0.00%
a rating ―
Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.
Premium Content
Find out which analyst has the highest Average Return & Success Rate
Go Premium
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0HI3 Analyst Recommendation Trends

Rating
Jan 24
Feb 24
Mar 24
Apr 24
May 24
Strong Buy
10
12
9
10
9
Buy
5
5
4
1
0
Hold
7
6
5
2
4
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
22
23
18
13
13
In the current month, 0HI3 has received 9 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. 0HI3 average Analyst price target in the past 3 months is $49.00.
Each month's total comprises the sum of three months' worth of ratings.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

0HI3 Financial Forecast

0HI3 Earnings Forecast

Next quarter’s earnings estimate for 0HI3 is -$0.52 with a range of -$1.11 to $0.00. The previous quarter’s EPS was -$1.02. 0HI3 beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 38.00% of the time in the same period. In the last calendar year 0HI3 has Underperformed its overall industry.
Next quarter’s earnings estimate for 0HI3 is -$0.52 with a range of -$1.11 to $0.00. The previous quarter’s EPS was -$1.02. 0HI3 beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 38.00% of the time in the same period. In the last calendar year 0HI3 has Underperformed its overall industry.

0HI3 Sales Forecast

Next quarter’s sales forecast for 0HI3 is $52.87M with a range of $0.00 to $80.00M. The previous quarter’s sales results were $0.00. 0HI3 beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 46.15% of the time in the same period. In the last calendar year 0HI3 has Underperformed its overall industry.
Next quarter’s sales forecast for 0HI3 is $52.87M with a range of $0.00 to $80.00M. The previous quarter’s sales results were $0.00. 0HI3 beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 46.15% of the time in the same period. In the last calendar year 0HI3 has Underperformed its overall industry.

0HI3 Stock Forecast FAQ

What is GB:0HI3’s average 12-month price target, according to analysts?
Based on analyst ratings, Arrowhead Pharmaceuticals’s 12-month average price target is $49.00.
    What is GB:0HI3’s upside potential, based on the analysts’ average price target?
    Arrowhead Pharmaceuticals has 97.58% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Arrowhead Pharmaceuticals a Buy, Sell or Hold?
          Arrowhead Pharmaceuticals has a consensus rating of Moderate Buy, which is based on 5 buy ratings, 3 hold ratings and 0 sell ratings.
            What is Arrowhead Pharmaceuticals’s share price target?
            The average share price target for Arrowhead Pharmaceuticals is $49.00. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is $90.00 ,and the lowest forecast is $27.00. The average share price target represents 97.58% Increase from the current price of $24.8.
              What do analysts say about Arrowhead Pharmaceuticals?
              Arrowhead Pharmaceuticals’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 8 Wall Streets Analysts.
                How can I buy shares of Arrowhead Pharmaceuticals?
                To buy shares of GB:0HI3, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis